XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Revenue (Details) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Net Product Sales [Abstract]        
Net product sales $ 249,172,000 $ 5,468,000 $ 576,622,000 $ 14,934,000
Activity of Sales Related Deductions [Roll Forward]        
Balance as of December 31, 2011     2,218,000  
Provision related to current period sales     44,471,000  
Credits/payments     (25,225,000)  
Balance as of September 30, 2012 21,464,000   21,464,000  
Rebates and Chargebacks
       
Activity of Sales Related Deductions [Roll Forward]        
Balance as of December 31, 2011     585,000  
Provision related to current period sales     10,021,000  
Credits/payments     (7,185,000)  
Balance as of September 30, 2012 3,421,000   3,421,000  
Distribution Related Fees
       
Activity of Sales Related Deductions [Roll Forward]        
Balance as of December 31, 2011     1,451,000  
Provision related to current period sales     31,545,000  
Credits/payments     (16,847,000)  
Balance as of September 30, 2012 16,149,000   16,149,000  
Other Sales Related Deductions
       
Activity of Sales Related Deductions [Roll Forward]        
Balance as of December 31, 2011     182,000  
Provision related to current period sales     2,905,000  
Credits/payments     (1,193,000)  
Balance as of September 30, 2012 1,894,000   1,894,000  
Customer concentration risk | Gross Sales Revenue
       
Risks and Uncertainties [Abstract]        
Concentration risk, percentage 79.00%   79.00%  
EYLEA
       
Net Product Sales [Abstract]        
Net product sales 244,400,000   561,900,000  
EYLEA | Collaboration Agreement with Bayer HealthCare LLC
       
Revenue Disclosure [Line Items]        
Substantive milestone payment 15,000,000      
ARCALYST
       
Net Product Sales [Abstract]        
Net product sales 4,800,000 5,500,000 14,700,000 14,900,000
ZALTRAP
       
Net Product Sales [Abstract]        
Net profit (loss) from commercialization of products under collaboration agreement (7,400,000)      
ZALTRAP | Collaboration Agreement with Sanofi
       
Revenue Disclosure [Line Items]        
Substantive milestone payment $ 50,000,000